Ribociclib
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Ribociclib
Jul 15, 2024, 12:03 |
Insight
Aleix Prat: Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared a post…
Jul 2, 2024, 08:37 |
Insight
How will we treat breast cancer 10 years from now?
Paolo Tarantino shared an article by Mattea Reinisch et al. on LinkedIn: …
Jun 13, 2024, 15:19 |
Blog
Recent news from Journal of Clinical Oncology about HR+/HER2-negative breast cancer - ASCO
ASCO (American Society of Clinical Oncology) shared a post on X/Twitter: ''Recent news from Journal…
May 23, 2024, 09:20 |
Blog
Yakup Ergün Summarizes Final Results of RIGHT Choice
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on X:…
May 8, 2024, 13:20 |
Drugs
CDK4 inhibitor on the horizon - Oncology Experts
Oncology Experts shared on LinkedIn: "PF-07220060, another CDK4 inhibitor on the horizon. Reported by Pfizer…
Apr 5, 2024, 18:16 |
Insight
Timothée Olivier: NATALEE trial, adjuvant ribociclib 21 days/28 for… 3 years! Cost alert!!
Timothée Olivier, Medical Oncologist at HUG - Geneva University Hospitals, shared a post by the…
Mar 21, 2024, 10:46 |
Insight
Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence - UCLA Health
Drug regimen significantly improves invasive disease-free survival for patients with stage 2 or 3 HR-positive,…
Feb 18, 2024, 10:00 |
Blog
Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: “How…
Jan 29, 2024, 10:53 |
Insight
Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO
Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard…
Jan 7, 2024, 15:14 |
Drugs
Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:…
Dec 21, 2023, 16:05 |
Insight
SABCS23 Day 4 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the fourth day's…
Dec 17, 2023, 17:26 |
Blog
25 Posts Not To Miss From SABCS 2023
The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…
Sep 8, 2023, 18:56 |
Drugs
,
Societies
ESMO Virtual Plenary: How does adjuvant ribociclib impact the health-related quality of life of patients with HR+/HER2-. - ESMO
Quoting ESMO - European Society of Medical Oncology, on Twitter: "ESMO Virtual Plenary: How does…
Jul 14, 2023, 19:34 |
Blog
Hepatotoxicity to Ribociclib is rather common (9% g3/g4) - Dr Sarah Sammons
Hepatotoxicity to Ribociclib is rather common (9% g3/g4). I have had 4 cases now responsive…
All:
14
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube